Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
School Asthma Care During COVID-19: What We Have Learned and What We Are Learning

Elissa M. Abrams, MD, MPH\textsuperscript{a}, Kamyron Jordan, MD\textsuperscript{b}, and Stanley J. Szeftler, MD\textsuperscript{b} \textit{Winnipeg, Man, Canada; and Aurora, Colo}

The focus of this article is to review school asthma care during coronavirus disease 2019 (COVID-19). Asthma is listed as a risk factor in some guidelines, although children with asthma appear to not be at increased risk of severe respiratory outcomes compared with children without asthma during the pandemic. Differentiating COVID-19 from allergic disease is very difficult in the school-aged children. For school management, there is firm evidence that masks do not exacerbate underlying lung conditions including asthma, and evidence to date supports that children with asthma can learn in-person at school because they do not appear to be at increased risk of COVID-19 morbidity or mortality. For children and adolescents, the COVID-19 vaccine has been demonstrated to be safe and well tolerated. School asthma management includes remaining on prescribed asthma medications. Asthma management, as with management of all pediatric conditions, must also factor in the impact of adverse social determinants and health disparities. Broadly, the pandemic has also served as a call to resource stewardship and innovation and allowed practitioners to consider how this may impact asthma care moving forward. © 2021 American Academy of Allergy, Asthma & Immunology (J Allergy Clin Immunol Pract 2022;10:453-9)

Key words: COVID-19; Asthma; Asthma therapeutics

INTRODUCTION

As of October 12, 2021, there have been over 238 million cases of coronavirus disease 2019 (COVID-19) worldwide, and over 4.8 million deaths.\textsuperscript{1} In the United States, there have been more than 44 million cases and more than 715,000 deaths to date. Although the impact of the global pandemic has been mitigated with mass international vaccination efforts, it remains in the forefront on the mind of clinicians and families across the globe.

The pandemic has had a broad direct and indirect impact on children and their families. Whereas children infected with COVID-19 have a better prognosis than adults\textsuperscript{2} and severe illness is less common,\textsuperscript{3} severe illness when it occurs can be significant among those admitted to hospital and is predicated by preexisting comorbidities.\textsuperscript{4} Data from the U.S. Centers for Disease Control and Prevention (CDC) has demonstrated that among the 96% of COVID-19 cases in which age was known, only 8.1% was among children younger than 18 years of age.\textsuperscript{4} However, morbidity can be high and there are racial and ethnic disparities in outcomes.\textsuperscript{5}

Although, in general, preschool- and school-aged children were at low risk of a direct impact of COVID-19 during the early waves of the pandemic,\textsuperscript{6} an increase in variants of concern has resulted in the possibility of increasing transmissibility rates to children as well as the possibility of increased morbidity and mortality.\textsuperscript{7} In addition, there is a rising recognition of other long-term complications being seen in the pediatric population—such as long COVID and multisystem inflammatory syndrome in children.\textsuperscript{8,9}

With the fall return to school, for families of children with asthma, as with families overall, there is significant concern about ensuring the safety and security of children. Specifically, there are concerns related to the risk that asthma poses to COVID-19 severity, and how broad public health measures impact children with asthma at school. Few articles have synthesized an approach to school-based management among children with underlying conditions such as asthma, who may be at real—or perceived—increased risk. As a result, the focus of this article is to review school asthma care during the pandemic (Figure 1).

IMPACT OF ASTHMA ON COVID-19 OUTCOMES IN CHILDREN

A major factor in parental comfort with school attendance among children with asthma is their risk should they acquire COVID-19 and, in particular, whether asthma places children at higher risk of severe COVID-19 outcomes. There are specific underlying chronic medical conditions that increase the risk of severe COVID-19 outcomes in children. These include obesity,
chronic lung disease, neurodevelopmental disorders and epilepsy, immunodeficiency, and older-aged children.

Whereas children with chronic lung disease are more likely to have severe or critical COVID-19, asthma has in general been an exception. In general, those with asthma are thought to be at low risk of COVID-19’s severe outcomes. A national prospective Canadian study of 264 children admitted to hospital with COVID-19 infection found that, although 39.3% of those children admitted had at least 1 comorbidity including chronic lung disease, asthma was an exception. A retrospective review of COVID-19 infection among children with asthma noted no increased COVID-19 severity independent of asthma severity and control over the year prior to the pandemic. In addition, a systematic review on asthma and COVID-19 in children noted no significant data that childhood asthma constitutes a risk factor for COVID-19 infection or severity. Although 1 report from the CDC found 11.5% of children with data had “chronic lung diseases including asthma” and 1 tertiary hospital reported asthma in 23.9% of children hospitalized for COVID-19, other studies have suggested perhaps even a protective risk associated with atopy. It has been demonstrated that downregulation of angiotensin-converting enzyme-2 expression on target cells (including in the lungs) due to T helper 2 cytokines may actually reduce the risk of COVID-19 infection in atopic children.

There is a concern that a rise in asthma exacerbations will be seen over the fall and spring this year; however, this was not noted during the first 3 waves of the pandemic. A study on asthma-related emergency department (ED) utilization in a high-volume U.S. children’s hospital found, for the year 2020, a dramatic reduction in asthma-related ED use (compared with the prior 4 years) that was significantly below historical seasonal variation. In addition, this pattern of a dramatic reduction was prior 4 years) that was significantly below historical seasonal variation.

In conclusion, studies to date have not demonstrated an increased risk of severe COVID-19 outcomes among children with asthma and have in fact noted a reduction in asthma health care utilization during COVID-19. Although further studies are required, and asthma remains listed as a risk factor in some guidelines, children with asthma appear to not be at increased risk of severe respiratory outcomes compared with children without asthma during the pandemic.

### SCHOOL-RELATED ISSUES IN CHILDREN WITH ASTHMA DURING COVID-19

#### Mask exemptions

Mask wearing, especially indoors, has emerged as a public health measure that significantly reduces transmission of COVID-19 and as a result has been, throughout the pandemic, mandated in schools. There has been significant misinformation that children with asthma should not wear masks because it may impact breathing and lung function. Mask mandates and exemptions have been described as a new frontier for clinicians and are a common request among families of children with asthma.

There is firm evidence that masks do not exacerbate underlying lung conditions. A cohort study of 47 infants and young children noted that surgical face masks were not associated with any changes in respiratory parameters nor clinical signs of respiratory distress. A recent scoping review on the impact of masks on cardiorespiratory response to exercise found that, whereas subjective sense of dyspnea may be increased with mask wearing, the objective effects on work of breathing, blood gases, and other physiological parameters are minimal with no sex-based or age-based differences detected. It has been noted by multiple international organizations, including the Canadian Thoracic Society, that there is “NO evidence that wearing a face mask will exacerbate (cause a ‘flare up’ of) an underlying lung condition.” In fact, the opposite may in fact be true. There is emerging evidence that wearing a face mask at school, and in other public places, can reduce spread of other common respiratory infections—such as respiratory syncytial virus and influenza—that are frequent causes of asthma exacerbations and might reduce the risk of viral-triggered asthma exacerbations at school in children. In conclusion, asthma is not an indication for a mask exemption in schools.

#### School attendance—differentiating asthma/allergic disease from COVID-19

A common frustration during the school year among families of children with asthma and other atopic conditions (in particular rhinitis) is differentiating allergic symptoms from those of COVID-19. This is particularly important to prevent children from missing school unnecessarily. However, unfortunately, differentiating COVID-19 from allergic disease is very difficult to do. The symptoms of COVID-19 can be pleiomorphic and include dramatic loss of taste and smell, gastrointestinal symptoms, and fever/myalgias, and with emerging strains, symptoms may change. However, dry cough and shortness of breath are among the most commonly presenting symptoms of both asthma as well as COVID-19. A study of 435 patients (although not pediatric) who presented for COVID-19 testing at a tertiary medical center noted a high overlap in symptoms of COVID-19 and worsening asthma. In fact, as noted by the American Academy of Allergy, Asthma, and Immunology (AAAAI), it is impossible to distinguish between a viral-induced asthma exacerbation and the symptoms of COVID-19. As a result, anyone symptomatic “should be considered to have COVID-19 until testing proves otherwise.”

---

**Abbreviations used**
- CDC: U.S. Centers for Disease Control and Prevention
- COVID-19: Coronavirus disease 2019
- ED: Emergency department
- ICS: Inhaled corticosteroids
- SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2

---

**FEBRUARY 2022**
A modified Delphi process has been used by the ARIA (Allergic Rhinitis and its Impact on Asthma)-EAACI (European Academy of Allergy and Clinical Immunology)-GA²LEN (Global Allergy and Asthma European Network) initiative to establish a set of questions aimed at distinguishing COVID-19 from allergic conditions. However, in the interim, it is very difficult to distinguish these conditions from COVID-19. As a result, if there are upper or lower respiratory symptoms, especially if atypical from a child’s standard allergic symptoms, COVID-19 testing is the only way to differentiate infection from allergic symptoms including asthma and rhinitis at the present time.

School attendance—virtual learning owing to asthma

Another common question is whether asthma is an indication for virtual learning during the pandemic. As previously described, the evidence to date supports that children with asthma can learn in-person at school because they do not appear to be at increased risk of COVID-19 morbidity or mortality. Children in general are less commonly symptomatic with COVID-19 than adults, and those who are symptomatic rarely require hospitalization, although morbidity may vary based on variants. Schools are not common vectors of COVID-19 transmission, and child-to-child transmission at schools has been rare, although this may change with variants of concern. A study of Irish notifications of all pediatric COVID-19 cases attending school found no evidence of transmission to other children or adults within the school, as well as a variety of other settings (including music lessons and choir practice). A retrospective study from Germany of school-aged children found child-to-child transmission at schools to be rare (estimated 1 secondary case per roughly 24 infectious school days) and “not the primary cause of SARS-CoV-2 [severe acute respiratory syndrome coronavirus 2] infection in children.” A study of nasopharyngeal swabs from 305 adults and pediatric COVID-19 cases in Canada noted that children, compared with adults, were less likely to grow virus in culture and had higher cycle thresholds and lower viral concentrations, “suggesting that children are not the main drivers of SARS-CoV-2 transmission.” A study of all school-aged cases of COVID-19 in Australia found only 2 possible cases of secondary school-based transmission (1 in high school, 1 from a staff member to a student) despite close contact with 735 students and 128 school staff. Regarding COVID-19 transmission, as stated in an editorial in Pediatrics, “the child is not to blame.”

Virtual learning is associated with environmental factors that could worsen asthma control including second-hand smoke exposure, prolonged exposure to indoor aeroallergens, and reduced physical activity. There is increasing recognition of the profound impact that remote learning (and its related consequences) has had on children and their families, in particular those facing adverse determinants of health. These include an
impact on school performance including lack of virtual platforms in some homes; lack of access to school-based medical programs and lunch programs, which could worsen food insecurity; impact on parental workforce; and broad mental health impacts. These adverse social determinants are also more likely to impact those with poorly controlled asthma.

At times, school closures are necessary from a broad public health perspective. However, on an individual level, when schools are open, asthma would not necessarily be an indication for virtual learning unless other considerations are present. In addition, more broadly, it has been identified that improving monitoring and learning assessment strategies will be critical for educators and policymakers to understand what system adjustments and additional support children will need to overcome the identified gaps in learning, especially for the foundational skills.

School attendance—COVID-19 vaccination

The COVID-19 vaccination provides the first opportunity to reduce the risk of severe COVID-19 outcomes. The vaccines are safe, immunogenic, and effective. The U.S. Food and Drug Administration (FDA) has provided an emergency use authorization for the Pfizer-BioNTech vaccine in adolescents aged 12 to 15 years, and children aged 5 to 11 years. However, broad vaccine hesitancy has been noted in families of adolescents within the United States, with a survey by the CDC noting that only 55.5% of parents/guardians of unvaccinated adolescents would definitely or probably allow their children to receive the COVID-19 vaccine. The CDC has noted that “efforts focusing on communicating the benefits and safety of COVID-19 vaccination for adolescents to the public could help increase adolescent COVID-19 vaccine confidence and vaccination coverage.”

As reports of allergic reactions to the mRNA COVID-19 vaccines emerged early in the pandemic, there is a common concern among allergic families, including families of adolescents with asthma, about the risk of an allergic reaction to the COVID-19 vaccine. Whereas the incidence of anaphylaxis post—COVID-19 vaccines is estimated at approximately 7.91 cases per million doses, which is higher than the historical incidence of vaccine anaphylaxis overall (of 1.3 cases per million doses), this remains an exceptionally rare outcome and, thus far, there has been no long-term morbidity nor mortality associated with COVID-19 vaccine anaphylaxis. Although those who have reported allergic reactions to the COVID-19 vaccine commonly have self-reported prior allergic conditions, these conditions are common in the general population, and the risk is impossible to quantify because the rate of individuals with allergic conditions who have tolerated the COVID-19 vaccine is not available. In addition, as data emerges that revaccination of individuals with an immediate reaction to a previous dose of COVID-19 vaccine is safe, and not influenced by testing to the vaccine or its excipients, there is increasing recognition these reactions are likely not allergen-driven nor immunoglobulin E–mediated. The CDC’s Advisory Committee on Immunization Practices’ (ACIP) recommends the use of the COVID-19 vaccine (Pfizer-BioNTech) in adolescents 12 years and older owing to its efficacy against symptomatic COVID-19 disease and to prevent community transmission of SARS-CoV-2, including among adolescents with allergic conditions. The only CDC indication for a vaccine exemption currently is a prior severe immediate reaction to a dose of the COVID-19 vaccine or its excipients. Adolescents with asthma and other allergic conditions, in the absence of this history, would not qualify for a vaccine exemption. The Global Initiative for Asthma (GINA) guideline recommends COVID-19 vaccination among those with asthma.

Another common concern is the use of asthma medications such as inhaled corticosteroids (ICS) and biologics, and whether the vaccine can be given while on these medications. Studies have shown the vaccine to be safe and well tolerated even if on asthma biologic therapy or steroid (whether oral or inhaled) therapy, although less data are available for the pediatric population. It is recommended that the COVID-19 vaccine and an asthma biologic not be given the same day (to differentiate the inciting agent should a reaction occur). Current asthma mediations (with the exception of oral steroid dose of 20 mg or greater prednisone or equivalent per day) are not considered immunosuppressive and are not currently an indication for a booster dose of the COVID-19 vaccine.

Vaccine hesitancy has also been described more commonly among those facing other adverse social determinants of health. In a survey study of 2,000 participants evaluating willingness to receive vaccination, attributes associated with a lower willingness to receive vaccination included lack of insurance (P < .001), lower educational attainment (P < .001), and non-White race. These adverse determinants are also associated both with asthma morbidity and COVID-19 risk.

Asthma management

Pharmacological management has an essential role in optimizing asthma control for school-aged children with asthma. The GINA strategy, as well as the AAAAI and multiple other international guidelines, recommend remaining on prescribed asthma medications such as ICS and biologics during the pandemic. There is no evidence that these medications increase the risk of COVID-19 infection and, paradoxically, in some studies ICS therapy has been protective against severe outcomes. Nebulization should be avoided if possible because it is aerosol generating. Influenza vaccination is recommended.

Asthma management during the pandemic must consider a more scoping approach to pediatric health. It is essential to optimize other health conditions that could have a longer-term impact on asthma symptoms and outcomes (and more broad pediatric outcomes) during this time—such as obesity. Studies have documented astounding increases in screen time, reductions in physical activity, and increases in obesity rates among children during the pandemic. Obesity has emerged as a factor in children associated with poorer COVID-19 outcomes. In a cross-sectional study of 43,465 children and adolescents, the strongest risk factors for COVID-19 hospitalization included obesity (adjusted ratio 3.07; 95% CI: 2.66–3.54). With respect to asthma, obesity increases the sensation of dyspnea, increases airway hyper-responsiveness, impairs immune function, and potentially reduces response to ICS therapy. More globally, obesity in childhood increases the risk of a multitude of other health conditions over the course of a lifetime including cardiovascular disease.

Asthma management, as with management of all pediatric conditions, must also factor in the impact of adverse social determinants and health disparities. Multiple determinants of health, including housing quality, poverty, health care access,
health literacy, and race and ethnicity, all have an impact on asthma (and COVID-19) outcomes. At the individual clinician level, and more broadly at the guideline and policy level, steps are required to ensure social determinants are considered in the approach to a family with asthma both during and after the pandemic.

Broadly, the pandemic has also served as a call to resource stewardship and innovation and allowed practitioners to consider how this may impact asthma care moving forward. One such example is step-up or step-down therapy. Whereas remaining on current asthma medications is generally recommended, little guidance is specifi
cation of virtual learning. Asthma management consists of medications. A school-based telemedicine approach would reduce school absence, reduce parental leave, and allow the potential for application of digital health for monitoring exacerbations and adherence to asthma medications.

Another example of innovative provision of care is the use of virtual care and telehealth visits, which has emerged as an opportunity to improve access, reduce health disparities, and prevent potential viral exposure in clinical settings during the pandemic. A study of children with asthma residing in 2 remote locations who were offered the choice of an in-person or telemedicine session noted comparable asthma control between the 2 visit types, with high family satisfaction among those who chose the telemedicine encounter. School-based telemedicine interventions have also been studied and are a novel approach to ongoing asthma care especially among underserved families, including those living in remote locations. A school-based telemedicine approach would reduce school absence, reduce parental leave, and allow the potential for application of digital health for monitoring exacerbations and adherence to asthma medications.

DISCUSSION

There is no evidence that asthma increases the risk of severe COVID-19 outcomes nor that COVID-19 causes severe asthma exacerbations among school-aged children. Asthma is not an indication for a mask exemption nor for a COVID-19 vaccine exemption. It is also not necessarily an indication for consideration of virtual learning. Asthma management consists of remaining on current asthma medications, though step-up or step-down therapy could be considered based on circumstances. More broadly, asthma management during the pandemic must factor in other comorbidities that can worsen asthma control—such as obesity—as well as more broadly the impact of adverse determinants of health. Finally, unprecedented times call for unprecedented change, and this is being seen in the approach to home-based and virtual care.

REFERENCES

1. Johns Hopkins University & Medicine. COVID-19 Map: Johns Hopkins Coronavirus Resource Center. Accessed December 23, 2021. https://coronavirus.jhu.edu/map.html
2. Hwang A, Chorath K, Moreira A, Evans M, Burmeister-Morton F, Burmeister F, et al. COVID-19 in 7764 pediatric patients: a systematic review. EClinicalMedicine 2020;24:100433.
3. Shekderdemian LS, Mahmood NR, Wolfe KK, Riggs BJ, Ross CE, McKiernan CA, et al. Characteristics and outcomes of children with coronavirus disease 2019 (COVID-19) infection admitted to US and Canadian pediatric intensive care units. JAMA Pediatr 2020;174:648-61.
4. Centers for Disease Control and Prevention. CDC COVID data tracker. Accessed December 23, 2021. https://covid.cdc.gov/covid-data-tracker/
   #demographics.
5. Centers for Disease Control and Prevention. Hospitalization rates and characteristics of children aged <18 years hospitalized with laboratory-confirmed COVID-19—COVID-NET. 14 states, March 1–July 5, 2020. MMWR Morb Mortal Wkly Rep 2020;69:1081-8.
6. Drouin O, Hepburn CM, Farrar DS, Baerg K, Chan K, Cyr C, et al. Characteristics of children admitted to hospital with acute SARS-CoV-2 infection in Canada in 2020. CMAJ 2021;193:E1483-93.
7. Khateeb J, Li Y, Zhang H. Emerging SARS-CoV-2 variants of concern and potential intervention approaches. Crit Care 2021;25:244.
8. Centers for Disease Control and Prevention. For parents: multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19. Accessed December 23, 2021. https://www.cdc.gov/mis/mis-c.html
9. Thomson H. Children with long COVID. New Sci 2021;249:10-1.
10. Canadian Paediatric Society. Position Statement: COVID-19 vaccine for children 12 years and older. Accessed December 23, 2021. https://www.cps.ca/en/documents/position/covid-19-vaccine-for-children#ref3
11. Mendes NF, Jara CP, Mansour E, Araújo EP, Veloso LA, Asthma and COVID-19: a systematic review. Allergy Asthma Clin Immunol 2021;17:5.
12. Franco PA, Jezler S, Cruz AA. Is asthma a risk factor for coronavirus disease-2019 worse outcomes? The answer is no, but … Curr Opin Allergy Clin Immunol 2021;21:223-8.
13. Ruano FJ, Somoza Álvarez ML, Haroun-Diaz E, Vázquez de la Torre M, López González F, Prieto-Moreno A, et al. Impact of the COVID-19 pandemic in children with allergic asthma. J Allergy Clin Immunol Pract 2020;8:3172-3174.e1.
14. Parri N, Lenge M, Buonsenso D. Children with COVID-19 in pediatric emergency departments in Italy. N Engl J Med 2020;383:187-90.
15. Van Bever HP, Chng SY, Goh DY. Childhood severe acute respiratory syndrome, coronavirus infections and asthma. Pediatr Allergy Immunol 2004;15:206-9.
16. Lu X, Zhang L, Du H, Zhang J, Li YY, Qiu J, et al. SARS-CoV-2 infection in children. N Engl J Med 2020;382:1663-5.
17. Wang Y, Ao G, Qi X, Xie B. The association between COVID-19 and asthma: a systematic review and meta-analysis. Clin Exp Allergy 2020;50:1274-7.
18. Castro-Rodriguez JA, Forno E. Asthma and COVID-19 in children: a systematic review and call for data. Pediatr Pulmonol 2020;55:2412-8.
19. CDC COVID-19 Response Team. Coronavirus disease 2019 in children—United States, February 12–April 2, 2020. MMWR Morb Mortal Wkly Rep 2020;69:422-6.
20. Bögiztopouloa A, Mayberry H, Hawcctib DB, Whittaker E, Munro A, Roland D, et al. COVID-19 in children: what did we learn from the first wave? Paediatr Child Health (Oxford) 2020;30:438-43.
21. Liu S, Zhi Y, Ying S. COVID-19 and asthma: reflection during the pandemic. Clin Rev Allergy Immunol 2020;59:78-88.
22. Wang J-Y, Pawankar R, Tsai H-J, Wu S-HL, Kuo W-S. COVID-19 and asthma, the good or the bad? Allergy 2021;76:565-7.
23. Jackson DJ, Busse WW, Bacharier LB, Kattan M, O’Connor GT, Wood RA, et al. Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2. J Allergy Clin Immunol 2020;146:203-206.e3.
24. Krivec U, Kofol Seliger A, Tursic J. COVID-19 lockdown dropped the rate of paediatric asthma admissions. Arch Dis Child 2020;105:809-10.
25. Kenyon CC, Hill DA, Henrickson SE, Bryant-Stephens TC, Zorc JJ. Initial effects of the COVID-19 pandemic on pediatric asthma emergency department utilization. J Allergy Clin Immunol Pract 2020;8:2774-2776.e1.
26. Navalpakkam A, Secord E, Pansare M. The impact of coronavirus disease 2019 on pediatric asthma in the United States. Pediatr Clin North Am 2021;68:1119-31.
27. Levene R, Fein DM, Silver EJ, Joels JR, Khine H. The ongoing impact of COVID-19 on asthma and pediatric emergency health-seeking behavior in the Bronx, an epicenter. Am J Emerg Med 2021;43:109-14.
28. Taquechel K, Dwibhatkar AR, Sayed S, Dudley JW, Grundmeier RW, Kenyon CC, et al. Pediatric asthma health care utilization, viral testing, and air pollution changes during the COVID-19 pandemic. J Allergy Clin Immunol Pract 2020;8:3378-3387.e11.
29. Lavoie PM, Reicherz F, Solimano A, Langleyl J. Potential resurgence of respiratory syncytial virus in Canada. CMAJ 2021;193:E1140-1.
30. Fischer CB, Adrien N, Silguero JJ, Hopper JJ, Chowdhury AR, Merler W. Mask adherence and rate of COVID-19 across the United States. PLoS One 2021;16:e0249091.
31. Dorfman D, Raz M. Mask exemptions during the COVID-19 pandemic—a new frontier for clinicians. JAMA Health Forum 2020;1:e200810.
32. Canadian Thoracic Society. Canadian Thoracic Society recommendations regarding the use of face masks by the public during the SARS-CoV-2 (COVID-19) pandemic. Accessed December 23, 2021. https://clinician.cpsc.gc.ca/Resources/PublicHealth/COVID-19-Related-Facts/20201021-Face-Mask-Position-Statement-1-2.pdf.
33. Soriano JB, Anzueto A, Bosnic Anticevich S, Kaplan A, Miravitlles M, Usmani O, et al. Face masks, respiratory patients and COVID-19. Eur Respir J 2020;56:2003325.
34. Lubran R, Blosse S, Testa A, Marcellino A, Diilolo A, Mallardo S, et al. Assessment of respiratory function in infants and young children wearing face masks during the COVID-19 pandemic. JAMA Netw Open 2021;4:e210414.
35. Hopkins SR, Dominelli PB, Davis CK, Guenette JA, Luski AM, Molgat-Seon Y, et al. Face masks and the cardiorespiratory response to physical activity in health and disease. Ann Am Thorac Soc 2021;18:399-407.
36. American Academy of Pediatrics. Face masks. November 15, 2021. Accessed December 23, 2021. https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-information-for-basic-public/face-masks/
37. Abrams EM, Sze.
38. Cao L, Lee S, Krings JG, Rauseo AM, Reynolds D, Presti R, et al. Asthma in children and adolescents during the COVID outbreak: ARIA-EAACI-GA(2) LEN consensus. Allergy 2021;76:2354-66.
39. American Academy of Allergy, Asthma & Immunology. School attendance, asthma, and return to school. Lancet Respir Med 2020;8:847-9.
40. Walter EB, Talaat KR, Sabharwal C, Gurtman A, Lockhart S, et al. Asthma and COVID-19: the known, the unknown, and the controversial. Pediatr Pulmonol 2021;56:2003325.
41. Abrams EM, Shaker M, Greenhawt M. School attendance, asthma risk, and COVID-19 in children. J Allergy Clin Immunol Pract 2021;9:2145-50.
42. Abrams EM, Shaker M, Greenhawt M, Akin C, Khan D, Chu DK, et al. The impact of COVID-19 on the health and education of children and adolescents. J Allergy Clin Immunol Pract 2021;9:E551.
43. Abrams EM, Shaker M, Greenhawt M, de Sacco L, Khan D, Akin C, et al. COVID-19 vaccines: safety and efficacy and the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med 2020;383:2603-15.
44. Baden LR, El Sahly HM, Essink B, Koutoloph K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021;384:36-47.
45. Centers for Disease Control and Prevention. COVID-19 vaccines for children and teens. Accessed December 23, 2021. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/adolescents.html
46. Abrams EM, Shaker M, Sinha I, Greenhawt M. COVID-19 vaccines: addressing hesitancy in young people with allergies. Lancet Respir Med 2021;9:1090-2.
47. Greenhawt M, Abrams EM, Shaker M, Chu DK, Khan D, Akin C, et al. The risk of allergic reaction to SARS-CoV-2 vaccines and recommended evaluation and management: a systematic review, meta-analysis, GRADE assessment, and international consensus approach. J Allergy Clin Immunol 2021;9:3546-67.
48. Kelso JM, Greenhawt MJ, Li JT, Nicklas RA, Bernstein DI, Blessing-Moore J, et al. Adverse reactions to vaccines practice parameter 2012 update. J Allergy Clin Immunol 2012;130:25-43.
49. Kranz MS, Kwah JH, Stone CA Jr, Phillips EJ, Ortega G, Banerji A, et al. Safety evaluation of the second dose of messenger RNA COVID-19 vaccines in patients with immediate reactions to the first dose. Allergy 2021;76:3538-40.
50. Kranz MS, Brunsgaard-Mortensen MA, Koo G, Phillips EJ, Stone CAJ, Garvey LH. Anaphylaxis to the first dose of mRNA SARS-CoV-2 vaccines: don’t give up on the second dose. Allergy 2021;76:2916-20.
51. Kelso JM. Misdiagnosis of systemic allergic reactions to mRNA COVID-19 vaccines. Annals Allergy Asthma Immunol 2021;127:133-4.
52. Wolfsön AR, Robinson LB, Li L, McMahon AE, Cogan AS, Fu X, et al. First-dose mRNA COVID-19 vaccine allergic reactions: limited role for eczematous skin testing. J Allergy Clin Immunol Pract 2021;9:3308-3320.e3.
53. Pitlick MM, Sitek AN, Kinata SA, Joshi AY, Park MA. Polyethylene glycol and polysorbate skin testing in the evaluation of coronavirus disease 2019 vaccine reactions: early report. Annals Allergy Asthma Immunol 2021;126:735-8.
54. Wallace M, Woodworth KR, Gargano JW, et al. The Advisory Committee on Immunization Practices’ interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine in adolescents aged 12–15 years—United States, May 2021. MMWR Morb Mortal Wkly Rep 2021;70:749-52.
55. Global Initiative for Asthma. GINA guidance about COVID-19 and asthma. Accessed December 23, 2021. https://ginasthma.org/wp-content/uploads/2021/03/2021_GINA-COVID-19-and-asthma.pdf
56. Bianchi F, et al. COVID-19 vaccination in patients with severe asthma on biologic treatment: safety, tolerability, and impact on disease control. Vaccines 2021;9:853.
VOLUME 10, NUMBER 2
J ALLERGY CLIN IMMUNOL PRACT
ABRAMS ET AL
459

76. American Academy of Asthma, Allergy & Immunology. COVID-19 and asthma: what patients need to know. Accessed January 4, 2022. https://www.aaaai.org/Tools-for-the-Public/Conditions-Library/Asthma/covid-prevent

77. American College of Allergy, Asthma, & Immunology. COVID-19, asthma and allergies. November 3, 2021. Accessed January 4, 2022. https://acaai.org/resources/covid-19/

78. Centers for Disease Control and Prevention. How to talk with patients who are immunocompromised. Accessed December 23, 2021. https://www.cdc.gov/vaccines/covid-19/bcp/immunocompromised-patients.html

79. Hildreth JE, Akendor DI. Targeting COVID-19 vaccine hesitancy in minority populations in the US: implications for herd immunity. Vaccines (Basel) 2021;9:489.

80. Kreps S, Prasad S, Brownstein JS, Hwenn Y, Garibaldi BT, Zhang B, et al. Factors associated with US Adults’ likelihood of accepting COVID-19 vaccination. JAMA Netw Open 2020;3:e202594.

81. Cañete C, Silva C, Mayer S, Mariani V, Wainwright CE, Zhang L. Inhaled corticosteroids and respiratory infections in children with asthma: a meta-analysis. Pediatrics 2017;139:e20163271.

82. Williamsen EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020;584:430-6.

83. Armitage LC, Brettell R. Inhaled corticosteroids: A rapid review of the evidence for treatment or prevention of COVID-19. J Allergy Clin Immunol Pract 2020;8:1808-14.

84. Flores G, Snowden-Bridon C, Torres S, Perez R, Walter T, Brotnak J, et al. Urban minority children with asthma: substantial morbidity, compromised quality and access to specialists, and the importance of poverty and specialty care. J Asthma 2009;46:392-8.

85. Flores G, Tornamy-Korman SC. Racial and ethnic disparities in medical and dental health, access to care, and use of services in US children. Pediatrics 2008;121:e286-98.

86. Abrams EM, Szefer SG, Oppenheimer J, Stukus D, Abrams EM, Mayell SJ, et al. The impact of social determinants of health on children with asthma. J Allergy Clin Immunol Pract 2020;8:1808-14.

87. Antoon JW, Grijalva CG, Thrush C, Richardson T, Spaulding AB, Teufel RJ II, et al. Factors associated with COVID-19 disease severity in US children and adolescents. J Hosp Med 2021;16:603-10.

88. Komarney L, Agathis NT, Nelson JM, Preston LE, Ko JY, Belay B, et al. Underlying medical conditions associated with severe COVID-19 illness among children. JAMA Netw Open 2021;4:e211182.

89. Beuther DA. Obesity and asthma. Clin Chest Med 2009;30:479-88.

90. Hay C, Henricksen SE. The impact of obesity on immune function in pediatric asthma. Curr Opin Allergy Clin Immunol 2021;21:202-15.

91. Park MH, Falconer C, Viner RM, Kinra S. The impact of childhood obesity on morbidity and mortality in adulthood: a systematic review. Obes Rev 2012;13:985-1000.

92. Sommer A, Twigg G. The impact of childhood and adolescent obesity on cardiovascular risk in adulthood: a systematic review. Curr Diab Rep 2018;18:91.

93. Sinha IP, Lee AR, Bennett D, McGreghan L, Abrams EM, Mayell SJ, et al. Child poverty, food insecurity, and respiratory health during the COVID-19 pandemic. Lancet Respir Med 2020;8:762-3.

94. Federico MJ, McFarlane A, Szefler SJ, Abrams EM. The impact of social determinants of health on children with asthma. J Allergy Clin Immunol Pract 2020;8:1808-14.

95. Flores G, Snowden-Bridon C, Torres S, Perez R, Walter T, Brotnak J, et al. Urban minority children with asthma: substantial morbidity, compromised quality and access to specialists, and the importance of poverty and specialty care. J Asthma 2009;46:392-8.

96. Sommer A, Twigg G. The impact of childhood and adolescent obesity on cardiovascular risk in adulthood: a systematic review. Curr Diab Rep 2018;18:91.

97. Sinha IP, Lee AR, Bennett D, McGreghan L, Abrams EM, Mayell SJ, et al. Child poverty, food insecurity, and respiratory health during the COVID-19 pandemic. Lancet Respir Med 2020;8:762-3.

98. Federico MJ, McFarlane A, Szefler SJ, Abrams EM. The impact of social determinants of health on children with asthma. J Allergy Clin Immunol Pract 2020;8:1808-14.

99. Flores G, Snowden-Bridon C, Torres S, Perez R, Walter T, Brotnak J, et al. Urban minority children with asthma: substantial morbidity, compromised quality and access to specialists, and the importance of poverty and specialty care. J Asthma 2009;46:392-8.

100. Flores G, Tornamy-Korman SC. Racial and ethnic disparities in medical and dental health, access to care, and use of services in US children. Pediatrics 2008;121:e286-98.

101. Abrams EM, Singer AG, Shaker M, Greenhawt M. What the COVID-19 pandemic can teach us about resource stewardship and quality in health care. J Allergy Clin Immunol Pract 2021;9:608-12.

102. Abrams EM, Szefler S. Ongoing asthma management in children during the COVID-19 pandemic: to step down or not to step down? Lancet Respir Med 2021;9:820-2.

103. Shaker MS, Moosain G, Oppenheimer J, Stukus D, Abrams EM, Greenhawt M. Health and economic outcomes of home maintenance allergen immunotherapy in select patients with high health literacy during the COVID-19 pandemic: a cost-effectiveness analysis during exceptional times. J Allergy Clin Immunol Pract 2020;8:2310-21.

104. Shaker M, Briggs A, Dibouk A, Dutille E, Oppenheimer J, Greenhawt M. Estimation of health and economic benefits of clinic versus home administration of omalizumab and mepolizumab. J Allergy Clin Immunol Pract 2020;8:565-72.

105. Portnoy JM, Waller M, De Lurgio S, Dinakar C. Telemedicine is as effective as in-person visits for patients with asthma. Ann Allergy Asthma Immunol 2016;117:241-5.

106. Perry TT, Margiotta CA. Implementing telehealth in pediatric asthma. Pediatr Clin North Am 2020;67:623-7.

107. Perry TT, Turner JH. School-based telemedicine for asthma management. J Allergy Clin Immunol Pract 2019;7:2524-32.